OOIR: Observatory of International Research

Papers

(The H4-Index of Blood Advances is 56. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Smith CC, Levis MJ, Perl AE, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155.	254
Abramson JS, Siddiqi T, Garcia J, et al. Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel–treated patients in the TRANSCEND NHL 001 trial. Blood Adv. 2021;5(6)	221
Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study	184
Addressing and overcoming disparities in GVHD	145
Predictors of liver disease outcomes in individuals with hemophilia and HCV infection	134
On a collision course: SARS-CoV-2 variants and CAR T cells	130
Genome editing of patient-derived iPSCs identifies a deep intronic variant causing aberrant splicing in hemophilia A	124
Distribution and prognostic impact of LymphGen subtypes in Korean diffuse large B-cell lymphoma using clinical NGS panel	118
Structural analysis of platelet fragments and extracellular vesicles produced by apheresis platelets during storage	118
Targeting Aurora kinase A to prevent GVHD and relapse after myeloablative allogeneic hematopoietic cell transplantation	117
Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses	113
Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia	106
Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma	104
Pirfenidone for the treatment of bronchiolitis obliterans syndrome related to chronic graft-versus-host disease	97
The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online tool	96
Sickle cell disease is a risk factor for transplant-associated thrombotic microangiopathy in children	92
Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes	88
LMWH prevents thromboinflammation in the placenta via HBEGF-AKT signaling	88
Ibrutinib plus rituximab vs ibrutinib monotherapy in patients with Waldenström macroglobulinemia: a pooled analysis	86
Cortisol in sickle cell disease: a systematic review and meta-analysis	86
Kennedy VE, Wong C, Huang C-Y, et al. Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma. Blood Adv.	85
Pirillo C, Birch F, Tissot FS, et al. Metalloproteinase inhibition reduces AML growth, prevents stem cell loss, and improves chemotherapy effectiveness. Blood Adv.	83
Campbell BA, Dobos G, Haider Z, et al. International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies. Blood	79
A Nested Case-Control Study of Monoclonal Gammopathy of Undetermined Significance in the Multiethnic Cohort Study.	79
Matrix stiffness controls megakaryocyte adhesion, fibronectin fibrillogenesis, and proplatelet formation through Itgβ3	78

Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea	78
ASCT vs CART for patients with relapsed LBCL in PR: role of TMTV	78
Long-term survival with sickle cell disease: a nationwide cohort study of Medicare and Medicaid beneficiaries	77
Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years	76
Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell–mediated tumor responses	76
Longitudinal clinical data improve survival prediction after hematopoietic cell transplantation using machine learning	74
Converting IMPROVE bleeding and VTE risk assessment models into a fast-and-frugal decision tree for optimal hospital VTE prophylaxis	72
Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel	69
CAR T cells targeting CCR4 selectively deplete human Tregs ex vivo and in vivo	69
CD58 loss in tumor cells confers functional impairment of CAR T cells	68
Infections and parameters of humoral immunity with talquetamab in relapsed/refractory multiple myeloma in MonumenTAL-1	65
Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia	65
Real-world comparison of progression-free survival and time to next therapy in 761 patients with newly diagnosed multiple myeloma	65
Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry	64
Transfusion therapy for sickle cell disease: what’s new?	64
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML	64
Best but not perfect: indirect measure of low iron stores	63
Selective modulation of activated protein C activities by a nonactive site–targeting nanobody library	62
Megakaryocyte/platelet-derived TGF-β1 inhibits megakaryopoiesis in bone marrow by regulating thrombopoietin production in liver	62
Deep PIM kinase substrate profiling reveals new rational cotherapeutic strategies for acute myeloid leukemia	62
Reduced FVIII recovery associated with anti-FVIII PEG antibodies after BNT162b2 SARS-CoV-2 vaccination	60
Glucagon-like peptide 1 receptor agonists and venous thromboembolism in type 2 diabetes: a target trial emulation	59
A mouse model for hemoglobin SC disease recapitulates characteristic human pathologies	58
Persistence of PET Scan Positivity After Chemoimmunotherapy For DLBCL	58
Applying CRISPR-Cas9 screens to dissect hematological malignancies	58
Priapism before and after hematopoietic stem cell therapy in individuals with sickle cell disease	57
Bite-size introduction to canine hematologic malignancies	57
Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma	57
Desensitization to calaspargase pegol appears to be less successful than pegaspargase	57
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium	56
Targeting bone marrow mesenchymal stromal cell–derived IL-6 to overcome acute myeloid leukemia chemoresistance	56
Genetic landscapes and curative effect of CAR T-cell immunotherapy in patients with relapsed or refractory DLBCL	56
Stratifying survival: the role of social determinants of health on AML outcomes by ELN 2022 criteria	56
Cystic Fibrosis and Sickle Cell Disease Associated with Non-administration of VTE Prophylaxis in Hospitalized Adults	56